Effect of Dexmedetomidine on Renal Function and Delayed Graft Function After Kidney Transplantation
- Registration Number
- NCT03327389
- Lead Sponsor
- Yonsei University
- Brief Summary
The purpose of this study is to elucidate the effect of dexmedetomidine on renal function and delayed graft function after kidney transplantation
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 104
Inclusion Criteria
- adult (20-80 years old)
- patients undergoing elective kidney transplantation
Exclusion Criteria
- emergency surgery
- severe sinus bradycardia (<50 beats per min [bpm])
- second-degree or third-degree heart block
- decreased heart function (EF <30%)
- acute myocardial ischemia
- serious hepatic dysfunction (Child-Pugh class C)
- patients with known or suspected severe adverse reactions to DEX (or clonidine)
- treatment with clonidine or dexmedetomidine in the past 30 days
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Control (Group C) placebo 0.9% NaCl infusion during surgery 0.9% NaCl was infused at a rate of 0.4 μg/kg/h starting immediately after anesthetic induction and continued until skin closure Dexmedetomidine (Group D) Dexmedetomidine Dexmedetomidine infusion during surgery Dexmedetomidine was infused at a rate of 0.4 μg/kg/h starting immediately after anesthetic induction and continued until skin closure
- Primary Outcome Measures
Name Time Method Serum creatinine level postoperative 7 day
- Secondary Outcome Measures
Name Time Method level of serum creatinine maximum 30 days before surgery, 1 hour after surgery, 1 day, 2 day, 3 day, 5 day, 7 day after surgery blood urea nitrogen (BUN) maximum 30 days before surgery, 1 hour after surgery, 1 day, 2 day, 3 day, 5 day, 7 day after surgery fluid intake(intraoperative intake and output measured by the amount of fluid(crystalloid/colloid)(mL) and blood administered(mL)) during surgery, 1 day, 2 day, 3 day, 4 day, 5 day, 6 day, 7 day after surgery Neutrophil gelatinase-associated lipocalin (NGAL) maximum 30 days before surgery, 1 hour after surgery, 1 day, 2 day, 3 day, 5 day, 7 day after surgery urine output during surgery, 1 day, 2 day, 3 day, 4 day, 5 day, 6 day, 7 day after surgery incidence of delayed graft function 7 days after surgery cystatin C maximum 30 days before surgery, 1 hour after surgery, 1 day, 2 day, 3 day, 5 day, 7 day after surgery kidney ultrasound 1 week, 1 month after surgery, if possible inflammatory mediator (IL-18, Il-1b) level immediately after induction, immediately after vessel clamp, immediately after reperfusion, 1hour after surgery
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does dexmedetomidine utilize to improve renal function post-kidney transplantation?
How does dexmedetomidine compare to standard-of-care treatments in preventing delayed graft function after kidney transplantation?
Are there specific biomarkers that predict patient response to dexmedetomidine in kidney transplant outcomes?
What adverse events are associated with dexmedetomidine use in kidney transplant recipients and how are they managed?
What are the potential combination therapies involving dexmedetomidine for enhancing graft survival in kidney transplantation?
Trial Locations
- Locations (1)
Department of Anesthesiology and Pain Medicine, Yonsei University College of Medicine
🇰🇷Seoul, Korea, Republic of